A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis
ClinicalTrials.gov ID: NCT06028490
Sponsor: Zheng Liu ENT
Information provided by: Zheng Liu ENT, Tongji Hospital (Responsible Party)
Last Update Posted: 2023-09-11
Brief Summary:
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Official Title:
The Efficacy and Safety of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Conventional Treatment: A Randomized, Double-Blind, Placebo-controlled Investigator Initiated Trial.
Intervention / Treatment:
- Biological: GR1802 injection-1
- Biological: GR1802 injection-2
- Biological: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) | 2023-09-07 |
| Primary Completion (Estimated) | 2023-11 |
| Study Completion (Estimated) | 2023-11 |
| Enrollment (Estimated) | 90 |
| Study Type | Interventional |
| Phase | Phase 2 |
| Other Study ID Numbers |
2081-IIT-SAR |